CLL - When to treat, how to treat Andrew Pettitt Honorary consultant Haematologist, Clatterbridge Cancer Center (plus other things…) My credentials as a CLL doctor 18 years experience as a consultant specialising in CLL ~100 peer reviewed publications, most on CLL Member of NCRI CLL Subgroup s...
Testicular Cancer Diagnosis If a suspicious lump exists, the physician may order tests to assist in making the diagnosis. Testicular ultrasoundis an excellent way to evaluate lumps in the testicle. With ultrasound, the technician moves a wand over the area. Sound waves echo to form an image on...
The disease typically presents in elderly people, with a male predominance and a median age at diagnosis of 72 years [1].In this current special issue of Acta Haematologica, which is dedicated to the topic of CLL, we present a series of review articles that highlight recent innovations and ...
Currently, research to determine the role ofnon-myeloablative (a.k.a. "mini" transplants)in CLL is underway. Non-myeloablative transplants rely less on the toxicity of chemotherapy and more on the "graft-versus-leukemia" effect to treat cancer. This type of therapy may provide a treatment o...
diagnosis, including in some with stage I/II disease. Overall, these patients have a much shorter PFS after RT (~ 5-year PFS of 50% vs. 95%;n = 67) and after systemic chemoimmunotherapy (CIT) (3-year PFS 40% vs. 85%;n = 53), comparable to that of patients with ...
AJ Lanigan:Take a while. But whatever that number is, roughly 10% of those cells make up theimmune system. So we’re looking at 10 to 12 trillion cells. Now that’s more cells than you have brain and central nervous system. That’s more cells than you have skin. You know skin is...
How AI is Revolutionizing MDS Diagnosis Interviews | IMMUNOTHERAPY | CAR T-Cell Therapy Organ-Sparing TMLI Enhances AML Transplant Outcomes Jordyn Sava March 14th 2025 Article Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with a...
John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.Play Video John M. Burke, MD, of Rocky Mountain Cancer Centers, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates. Highligh...
The whole genome sequencing (WGS) test, designed by Haystack Analytics, aims to tackle the looming challenge of drug resistance. Apart from this, the test also helps in treating and preventing the spread of TB by providing a timely, affordable and accurate diagnosis....
The choice of stem cell depends on accessibility to the donor, disease diagnosis, urgency for the transplant, and centre preference (Elfeky et al.2019). 2.3.1Peripheral Blood Stem Cells PBSCs have been increasingly used in both auto- and allo-HSCT. Mobilization of haematopoietic stem cells to...